Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith L Knutson

Showing results (61-70 of 147) with videos related to

Pageof 15
Sort By:
Cancer Research|April 3, 2008
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumorsAndrea Worschech, Maciej Kmieciak, Keith L Knutson, et al.
Scientific Reports|August 9, 2020
Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanomaEmmanuel M Gabriel, Minhyung Kim, Daniel T Fisher, et al.
Immunotherapy|April 5, 2019
Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapyYanyan Lou, Julian A Marin-Acevedo, Prakash Vishnu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2004
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccineMary L Disis, Kathy Schiffman, Katherine Guthrie, et al.
The American Journal of Pathology|November 10, 2011
LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levelsJustin E Juskewitch, Bruce E Knudsen, Jeffrey L Platt, et al.
Gynecologic Oncology|January 29, 2008
Folate receptor alpha as a tumor target in epithelial ovarian cancerKimberly R Kalli, Ann L Oberg, Gary L Keeney, et al.
Surgical Oncology|August 30, 2024
Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomasNathan D Seligson, Yan W Asmann, Tariq Almerey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 10, 2011
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancerJames Krempski, Lavakumar Karyampudi, Marshall D Behrens, et al.
Journal of Translational Medicine|June 10, 2010
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialHåkan Norell, Isabel Poschke, Jehad Charo, et al.
Cytokine|March 7, 2015
Plasma immune analytes in patients with epithelial ovarian cancerMatthew S Block, Matthew J Maurer, Krista Goergen, et al.
Pageof 15

Showing results (61-70 of 147) with videos related to

Sort By:
Pageof 15
Cancer Research|April 3, 2008
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumorsAndrea Worschech, Maciej Kmieciak, Keith L Knutson, et al.
Scientific Reports|August 9, 2020
Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanomaEmmanuel M Gabriel, Minhyung Kim, Daniel T Fisher, et al.
Immunotherapy|April 5, 2019
Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapyYanyan Lou, Julian A Marin-Acevedo, Prakash Vishnu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2004
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccineMary L Disis, Kathy Schiffman, Katherine Guthrie, et al.
The American Journal of Pathology|November 10, 2011
LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levelsJustin E Juskewitch, Bruce E Knudsen, Jeffrey L Platt, et al.
Gynecologic Oncology|January 29, 2008
Folate receptor alpha as a tumor target in epithelial ovarian cancerKimberly R Kalli, Ann L Oberg, Gary L Keeney, et al.
Surgical Oncology|August 30, 2024
Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomasNathan D Seligson, Yan W Asmann, Tariq Almerey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 10, 2011
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancerJames Krempski, Lavakumar Karyampudi, Marshall D Behrens, et al.
Journal of Translational Medicine|June 10, 2010
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialHåkan Norell, Isabel Poschke, Jehad Charo, et al.
Cytokine|March 7, 2015
Plasma immune analytes in patients with epithelial ovarian cancerMatthew S Block, Matthew J Maurer, Krista Goergen, et al.
Pageof 15